RecruitingNCT05718726

Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI)

Overwhelming Post-Splenectomy Infections (OPSI) After Cytoreductive Surgery and Hyperthemic Intraperitoneal Chemotherapy: a Prospective Observational Study


Sponsor

Hampshire Hospitals NHS Foundation Trust

Enrollment

300 participants

Start Date

Mar 25, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The spleen is involved in maintaining immunity and plays an important role in the elimination of encapsulated bacteria and parasites. Patients who undergo splenectomy in conjunction with complete CRS for peritoneal malignancy are at risk of overwhelming post-splenectomy infections post-operatively. These patients are therefore administered vaccinations to lower the risk of infections but as they do not completely eliminate the risk, patients are also prescribed prophylactic antibiotics without clear evidence that they are useful in preventing OPSI. The use of prophylactic antibiotics is not without risk with potential short and long-term risks including resistance, interaction with other medication, clostridium difficile infections, fungal infections, other changes to the microbiome and cost. This study will investigate the incidence of OPSI post splenectomy and assess compliance with prophylactic antibiotics. This is an observational study where consented patients will be telephoned at fixed time points which are 1,6,12 weekly and 6 monthly for a period of five years post-operatively. As part of routine care patients will be telephoned by the clinical nurse specialist at weeks 1,6 and 12. In addition to this the research nurse will telephone the patient 6 monthly for a period of 5 years and complete a questionnaire. The research nurse will complete the questionnaire during each telephone call and this should not take more than 20 minutes. At the start of the telephone call, consent will be confirmed each time and the research nurse will check that the patient is still happy to participate before going ahead.


Eligibility

Min Age: 18 YearsMax Age: 79 Years

Inclusion Criteria1

  • \- Patients aged >18 and <80 years Patients capable of providing informed consent Patients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology

Exclusion Criteria1

  • \- Patients who are <18 and >80 Patients who do not provide informed consent Patients on immunosuppression therapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERQuestionnaire, interview or observation study

Questionnaire administered by telephone


Locations(1)

The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust

Basingstoke, Hampshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05718726


Related Trials